MAPT and Alzheimer disease: The cerebral tau load assessed by PET using various tau imaging tracers associates with brain regional atrophy assessed by using structural MRI and cognitive impairment in patients with AD (La Joie et al., 2020; Ossenkoppele et al., 2020, 2021; Vogel et al., 2021), CBD, and PSP (Robinson et al., 2020; Tagai et al., 2020; Whitwell et al., 2020).